Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

61. Association of habitual glucosamine use with risk of cardiovascular disease: prospective study in UK Biobank. Full Text available with Trip Pro

Association of habitual glucosamine use with risk of cardiovascular disease: prospective study in UK Biobank. To prospectively assess the association of habitual glucosamine use with risk of cardiovascular disease (CVD) events.Prospective cohort study.UK Biobank.466 039 participants without CVD at baseline who completed a questionnaire on supplement use, which included glucosamine. These participants were enrolled from 2006 to 2010 and were followed up to 2016.Incident CVD events, including CVD (...) death, coronary heart disease, and stroke.During a median follow-up of seven years, there were 10 204 incident CVD events, 3060 CVD deaths, 5745 coronary heart disease events, and 3263 stroke events. After adjustment for age, sex, body mass index, race, lifestyle factors, dietary intakes, drug use, and other supplement use, glucosamine use was associated with a significantly lower risk of total CVD events (hazard ratio 0.85, 95% confidence interval 0.80 to 0.90), CVD death (0.78, 0.70 to 0.87

2019 BMJ

62. Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial. There is concern that long-acting muscarinic antagonists increase cardiovascular morbidity or mortality in patients with chronic obstructive pulmonary disease (COPD).To determine the cardiovascular safety (noninferiority) and efficacy (superiority) of aclidinium bromide, 400 μg twice daily, in patients (...) with COPD and cardiovascular disease or risk factors.Multicenter, randomized, placebo-controlled, double-blind, parallel-design study conducted at 522 sites in North America. A total of 3630 patients with moderate to very severe COPD and either a history of cardiovascular disease or at least 2 atherothrombotic risk factors were randomized; follow-up occurred for up to 3 years until at least 122 major adverse cardiovascular events (MACE) occurred. The first patient was enrolled on October 16, 2013

2019 JAMA Controlled trial quality: predicted high

63. Glucose screening in pregnancy and future risk of cardiovascular disease in women: a retrospective, population-based cohort study (Abstract)

as a diagnosis on the delivery hospital record. The study population was divided into six groups based on the results of the glucose challenge test (≤4·8 mmol/L; 4·9-5·5 mmol/L; 5·6-6·2 mmol/L; 6·3-6·9 mmol/L; 7·0-7·9 mmol/L; and ≥8·0 mmol/L). The primary outcome was cardiovascular disease (a composite of hospitalisation for myocardial infarction, acute coronary syndrome, stroke, coronary artery bypass grafting, percutaneous coronary intervention, or carotid endarterectomy). All women were followed up from (...) Glucose screening in pregnancy and future risk of cardiovascular disease in women: a retrospective, population-based cohort study In studies to date, gestational diabetes has consistently been associated with an increased future risk of cardiovascular disease, irrespective of the antepartum screening protocol or diagnostic criteria by which gestational diabetes is diagnosed. We reasoned that the resultant heterogeneity in the severity of dysglycaemia in women with gestational diabetes suggests

2019 EvidenceUpdates

64. The Effects of Long-term CPAP on Weight Change in Patients With Comorbid OSA and Cardiovascular Disease: Data From the SAVE Trial Full Text available with Trip Pro

The Effects of Long-term CPAP on Weight Change in Patients With Comorbid OSA and Cardiovascular Disease: Data From the SAVE Trial Although recent evidence suggests that OSA treatment may cause weight gain, the long-term effects of CPAP on weight are not well established.This study was a post hoc analysis of the Sleep Apnea Cardiovascular Endpoints (SAVE) study, a multicenter, randomized trial of CPAP plus standard care vs standard care alone in adults with a history of cardiac (...) subjects without CPAP (mean difference, 0.38 kg [95% CI, 0.04 to 0.73]; P = .031), there were no between-group differences in other anthropometric variables, nor were there any differences between female high CPAP adherers and matched control subjects.Long-term CPAP use in patients with comorbid OSA and cardiovascular disease does not result in clinically significant weight change.ClinicalTrials.gov; No.: NCT00738179; URL: www.clinicaltrials.gov.Copyright © 2018 American College of Chest Physicians

2019 EvidenceUpdates

65. Bioresorbable Stents in cardiovascular indications (coronary artery disease)

Bioresorbable Stents in cardiovascular indications (coronary artery disease) Dec2015 © EUnetHTA, 2015. Reproduction is authorised provided EUnetHTA is explicitly acknowledged 1 EUnetHTA Joint Action 3 WP4 Version 1.4, 28 January 2019 Rapid assessment of other technologies using the HTA Core Model ® for Rapid Relative Effectiveness Assessment BIORESORBABLE STENTS FOR THE TREATMENT OF CARDIOVASCULAR INDICATIONS (CORONARY ARTERY DISEASE) Project ID: OTCA16 Bioresorbable stents for cardiovascular (...) and Confidentiality Undertaking of Interest (DOICU) statement form. How to cite this assessment Please cite this assessment as follows: IAMEV, SNSPMPDSB et al. Bioresorbable stents for the treatment of cardiovascular indications (coronary artery disease). Rapid assessment of other health technologies using the HTA Core Model for Rapid Relative Effectiveness Assessment. EUnetHTA Project ID: OTCA16. 2019. Bioresorbable stents for cardiovascular indications Version 1.4, 28 January 2019 EUnetHTA Joint Action 3 WP4 4

2019 EUnetHTA

66. Primary care management of cardiovascular risk for people with severe mental illnesses: the Primrose research programme including cluster RCT Full Text available with Trip Pro

the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} This research programme developed new ways of predicting cardiovascular disease risk for people with severe mental illnesses, but an evidence-based practitioner-led intervention in primary care did not reduce cholesterol more than treatment as usual. {{author}} {{($index , , , , , , , , , , , , , , , , , , , , , , , , , & . David (...) Primary care management of cardiovascular risk for people with severe mental illnesses: the Primrose research programme including cluster RCT Primary care management of cardiovascular risk for people with severe mental illnesses: the Primrose research programme including cluster RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from

2019 NIHR HTA programme

67. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease Arnett et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease Page 1 of 98 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, the American Geriatrics Society, the American (...) ://ahajournals.org by on April 25, 2019Arnett et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease Page 2 of 98 The American Heart Association requests that this document be cited as follows: Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaeian B. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease

2019 American Heart Association

68. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive summary Full Text available with Trip Pro

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive summary 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search April 2019 April 2019 April 2019 April 2019 March 2019 March 2019 March 2019 March 2019 March 2019 February 2019 February 2019 February 2019 February 2019 January 2019 January 2019 January 2019 January 2019 January (...) 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines , PhD, MSPH, FAHA, Co-Chair , MD, FACC, FAHA, Co-Chair , MD, MPH, FAHA , Esq , MD, MS, FACC, FAHA , PhD, RN , PhD, RN, ANP, FAHA

2019 American Heart Association

69. Water Pipe (Hookah) Smoking and Cardiovascular Disease Risk Full Text available with Trip Pro

Water Pipe (Hookah) Smoking and Cardiovascular Disease Risk Water Pipe (Hookah) Smoking and Cardiovascular Disease Risk: A Scientific Statement From the American Heart Association | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search April 2019 April 2019 April 2019 April 2019 March 2019 March 2019 March 2019 March 2019 March 2019 February 2019 February 2019 February 2019 February 2019 January 2019 January 2019 January 2019 January 2019 January 2019 (...) This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Water Pipe (Hookah) Smoking and Cardiovascular Disease Risk: A Scientific Statement From the American Heart Association , PhD, FAHA, Chair , PhD , PhD , PhD , ScD , PhD, MPH , PhD , PhD , PhD , MD, FAHA , PhD Aruni Bhatnagar , Wasim Maziak , Thomas Eissenberg , Kenneth D. Ward , George Thurston , Brian A. King , Erin L. Sutfin , Caroline O. Cobb

2019 American Heart Association

70. Primary Prevention of Cardiovascular Disease

Primary Prevention of Cardiovascular Disease Accepted Manuscript 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease WRITING COMMITTEE MEMBERS, Donna K. Arnett, PhD, MSPH, FAHA, Co-Chair, Roger S. Blumenthal, MD, FACC, FAHA, Co-Chair, Michelle A. Albert, MD, MPH, FAHA, Erin D. Michos, MD, MHS, FACC, FAHA, Andrew B. Buroker, Esq, Michael D. Miedema, MD, MPH, Zachary D. Goldberger, MD, MS, FACC, FAHA, Daniel Muñoz, MD, MPA, FACC, Ellen J. Hahn, PhD, RN, Sidney C. Smith, Jr (...) , Cigarroa JE, Joglar JA, Deswal A, Mauri L, Fleisher LA, Piano MR, Gentile F, Riegel B, Goldberger ZD, Wijeysundera DN, 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease, Journal of the American College of Cardiology (2019), doi: https://doi.org/10.1016/j.jacc.2019.03.010.This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting

2019 American College of Cardiology

71. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer

Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer 1 Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer Interim Guidance from the Kaiser Permanente National Integrated Cardiovascular Health (ICVH) Work Group October 5, 2018 Three randomized clinical trials (ARRIVE 1 , ASCEND 2 , and ASPREE 3 ) recently published results on aspirin use in patients without known Atherosclerotic Cardiovascular Disease (ASCVD). The studies looked at benefits including (...) daily. • There is no recommendation for or against aspirin therapy in adults aged < 50 or = 60 years. • Exclude adults with increased risk of bleeding. This includes those with a history of gastrointestinal (GI) bleeding, GI ulcers, intracranial bleed, bleeding disorders, renal failure, severe liver disease, thrombocytopenia, or using NSAIDS daily, or other medicine to prevent blood clots. The recommendations above reflect a change from initiate to consider in adults aged 50-59 years with 10-year

2019 Kaiser Permanente National Guideline Program

72. Associations of Dietary Cholesterol or Egg Consumption With Incident Cardiovascular Disease and Mortality. Full Text available with Trip Pro

Associations of Dietary Cholesterol or Egg Consumption With Incident Cardiovascular Disease and Mortality. Cholesterol is a common nutrient in the human diet and eggs are a major source of dietary cholesterol. Whether dietary cholesterol or egg consumption is associated with cardiovascular disease (CVD) and mortality remains controversial.To determine the associations of dietary cholesterol or egg consumption with incident CVD and all-cause mortality.Individual participant data were pooled from (...) 6 prospective US cohorts using data collected between March 25, 1985, and August 31, 2016. Self-reported diet data were harmonized using a standardized protocol.Dietary cholesterol (mg/day) or egg consumption (number/day).Hazard ratio (HR) and absolute risk difference (ARD) over the entire follow-up for incident CVD (composite of fatal and nonfatal coronary heart disease, stroke, heart failure, and other CVD deaths) and all-cause mortality, adjusting for demographic, socioeconomic

2019 JAMA

73. Mendelian Randomization Study of <i>ACLY</i> and Cardiovascular Disease. Full Text available with Trip Pro

Mendelian Randomization Study of ACLY and Cardiovascular Disease. ATP citrate lyase is an enzyme in the cholesterol-biosynthesis pathway upstream of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), the target of statins. Whether the genetic inhibition of ATP citrate lyase is associated with deleterious outcomes and whether it has the same effect, per unit decrease in the low-density lipoprotein (LDL) cholesterol level, as the genetic inhibition of HMGCR is unclear.We constructed (...) lifelong genetic inhibition of HMGCR was associated with an increased risk of cancer.Genetic variants that mimic the effect of ATP citrate lyase inhibitors and statins appeared to lower plasma LDL cholesterol levels by the same mechanism of action and were associated with similar effects on the risk of cardiovascular disease per unit decrease in the LDL cholesterol level. (Funded by Esperion Therapeutics and others.).Copyright © 2019 Massachusetts Medical Society.

2019 NEJM

74. Disease Damage Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Systemic Lupus Erythematosus (Abstract)

Disease Damage Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Systemic Lupus Erythematosus Composite scores of cardiovascular (CV) risk factors underestimate the CV risk in patients with systemic lupus erythematosus (SLE). Carotid artery ultrasound (US) was found useful in identifying high CV-risk patients with inflammatory arthritis. We assessed the effect of carotid US assessments on the CV risk stratification of patients with SLE.This cross (...) -sectional study included 276 patients with SLE. These indices were measured: lipid profile, Systematic COronary Risk Evaluation (SCORE) risk calculation, and disease activity (SLE Disease Activity Index), severity (Katz), and damage [Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology Damage Index]. Carotid plaques were assessed by US. A multivariable regression analysis, adjusted for classic CV-related factors, was performed to evaluate how risk reclassification

2019 EvidenceUpdates

75. Transition from metabolically benign to metabolically unhealthy obesity and 10-year cardiovascular disease incidence: the ATTICA cohort study (Abstract)

Transition from metabolically benign to metabolically unhealthy obesity and 10-year cardiovascular disease incidence: the ATTICA cohort study Metabolically benign obesity remains a scientific field of considerable debate. The aim of the present work was to evaluate whether metabolically healthy obese (MHO) status is a transient condition which propagates 10-year cardiovascular disease (CVD) onset.A prospective longitudinal study was conducted during 2001-2012, the ATTICA study studying 1514 (...) (49.8%) men and 1528 (50.2%) women (aged >18 years old) free of CVD and residing in the greater Athens area, Greece. Follow-up assessment of first combined CVD event (2011-2012) was achieved in n = 2020 participants; of them, 317 (15.7%) incident cases were identified. Obesity was defined as body mass index ≥30 kg/m2 and healthy metabolic status as absence of all NCEP ATP III (2005) metabolic syndrome components (excluding waist circumference).The MHO prevalence was 4.8% (n = 146) with 28.2

2019 EvidenceUpdates

76. Predicting Bleeding Risk to Guide Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Cohort Study. (Abstract)

Predicting Bleeding Risk to Guide Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Cohort Study. Many prognostic models for cardiovascular risk can be used to estimate aspirin's absolute benefits, but few bleeding risk models are available to estimate its likely harms.To develop prognostic bleeding risk models among persons in whom aspirin might be considered for the primary prevention of cardiovascular disease (CVD).Prospective cohort study.New Zealand primary care.The study (...) models included the following predictors: demographic characteristics (age, ethnicity, and socioeconomic deprivation), clinical measurements (systolic blood pressure and ratio of total-high-density lipoprotein cholesterol), family history of premature CVD, medical history (smoking, diabetes, bleeding, peptic ulcer disease, cancer, chronic liver disease, chronic pancreatitis, or alcohol-related conditions), and medication use (nonsteroidal anti-inflammatory agents, corticosteroids, and selective

2019 Annals of Internal Medicine

77. Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial. (Abstract)

Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial. The PCSK9 inhibitor evolocumab reduced low-density lipoprotein cholesterol and first cardiovascular events in the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial, but patients remain at high risk of recurrent cardiovascular events.To evaluate the effect of evolocumab on total (...) cardiovascular events, given the importance of total number of cardiovascular events to patients, clinicians, and health economists.Secondary analysis of a randomized, double-blind clinical trial. The FOURIER trial compared evolocumab or matching placebo and followed up patients for a median of 2.2 years. The study included 27 564 patients with stable atherosclerotic disease receiving statin therapy. Data were analyzed between May 2017 and February 2019.The primary end point (PEP) was time to first

2019 JAMA cardiology Controlled trial quality: predicted high

78. Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial. Full Text available with Trip Pro

Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial. Higher baseline high-sensitivity C-reactive protein (hsCRP) levels after an acute coronary syndrome (ACS) are associated with adverse cardiovascular outcomes. The usefulness of serial hsCRP measurements for risk stratifying patients after ACS is not well characterized.To assess whether longitudinal increases in hsCRP (...) measurements during the 16 weeks after ACS are independently associated with a greater risk of a major adverse cardiac event (MACE), all-cause death, and cardiovascular death.Secondary analysis of the double-blind, multicenter, randomized clinical Vascular Inflammation Suppression to Treat Acute Coronary Syndromes for 16 Weeks (VISTA-16) trial conducted between June 1, 2010, and March 7, 2012 (study termination on March 9, 2012), which included 5145 patients from 362 academic and community hospitals

2019 JAMA cardiology Controlled trial quality: predicted high

79. Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: a randomised controlled proof-of-concept trial. Full Text available with Trip Pro

Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: a randomised controlled proof-of-concept trial. The APPLE COPD-ICON2 trial is a prospective 2×2 factorial, double-blinded proof-of-concept randomised controlled trial targeting patients with chronic obstructive pulmonary disease (COPD) without prior history of cardiovascular disease. The primary goal of this trial is to investigate if treatment with antiplatelet (...) recruited with mean age of 67.5 years; 47.5% patients were male. The per-protocol ASPI test response rate to aspirin was 68.3% (95% CI 52.3-80.9%). The per-protocol ADP test response rate to ticagrelaor was 68.8% (95% CI 50.4-82.6%). Platelet response to antiplatelet therapy with aspirin and ticagrelor was not observed in nearly one-third of COPD patients without prior history of cardiovascular disease. These findings support the high pro-thrombotic milieu and the need for further research to determine

2019 ERJ open research Controlled trial quality: predicted high

80. Cardiovascular Benefits and Harms of Step Therapy in the Treatment of Type 2 Diabetes in Adults with and without Atherosclerotic Cardiovascular Disease

Cardiovascular Benefits and Harms of Step Therapy in the Treatment of Type 2 Diabetes in Adults with and without Atherosclerotic Cardiovascular Disease Cardiovascular Benefits and Harms of Step Therapy in the Treatment of Type 2 Diabetes in Adults with and without Atherosclerotic Cardiovascular Disease Kaiser Permanente Research Affiliates Evidence-based Practice Center Corinne Evans, MPP; Nicholas Emptage, MAE; Megan Rushkin, MPH; and Jennifer S. Lin, MD, MCR Summary Question 1. In persons (...) with type 2 diabetes with or without known atherosclerotic cardiovascular disease (ASCVD) who cannot attain adequate glucose control with metformin, what is the benefit of GLP-1 agonists or SGLT-2 inhibitors on cardiovascular morbidity and mortality? • Evidence of benefit in persons with known ASCVD on cardiovascular disease (CVD) outcomes, CVD mortality and all-cause mortality (ACM) o Based on limited evidence in persons without ASCVD, no evidence of benefit on CVD outcomes • Presumed class effect

2019 Kaiser Permanente National Guideline Program